MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.

Toni K. Choueiri,Laurence Albiges,Li Fan,Rodolfo F. Perini,Donna Vickery,Thomas Powles,Brian I. Rini

MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.

2021

Toni K. Choueiri
Laurence Albiges
Li Fan
Rodolfo F. Perini
Donna Vickery
Thomas Powles
Brian I. Rini

TPS368Background: In ccRCC, HIF-2α is involved in the activation of genes such as VEGFA, cyclin D1, and CXCR4, which are associated with angiogenesis, tumor progression, and metastasis. HIF-2α can ...

Keywords:

Cyclin D1
Angiogenesis
Cancer research
Clear cell renal cell carcinoma
Metastasis
Everolimus
Tumor progression
Vascular endothelial growth factor A
Medicine
Hypoxia-inducible factors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations